Pediatric Study Now Enrolling Patients with GPA or MPA!
Study to evaluate the safety and bodily absorption of intravenous Rituximab (RXT) in pediatric patients with severe granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis.
About this Study:
This study will evaluate the safety of Rituximab for treating pediatric patients with severe GPA and MPA and provide much needed data for treatment options.
Why is this study so important? And why participate?
Anca-Associated Vasculitis is a very rare condition in children and adolescents. It is estimated that there is less than 1 case per 2.75 MILLION cases a year. There is a serious lack of appropriate treatment options, and patients are needing primary therapy. Every patient that participates in this study helps to bring effective, and potentially life-saving, treatments one step closer.
Primary Study Objectives:
Evaluate the safety, tolerability and pharmacokinetics of Rituximab (RXT) in pediatric patients.
Measure how effective RTX is at inducing remission.
Study the effects of RTX on quality of life.
Who can join?
Are between the ages of 2 and 18
Have a diagnosis of GPA or MPA
Newly diagnosed OR patients with relapsing disease
How to join: